With weight loss candidates still in the clinic, the company has launched a health unit aimed at the flourishing therapeutic area.
Click's CT-155 commercialisation plan comes as regulatory-approved digital therapeutics experience strong market growth.
Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore ...
Boehringer Ingelheim and Click Therapeutics are restructuring their marketing deal for the software-based schizophrenia ...
The financing combines a $50M Series D investment by Boehringer Ingelheim with additional dedicated funding to support commercialization. As part ...
Boehringer Ingelheim] had little incentive to investigate the dangers in a product that was producing over $1 billion in ...
New York City Mayor Zohran Mamdani rallied to celebrate 100 days in office, boosting his early accomplishments and charting ...
"Achieving carbon neutrality in our owned manufacturing operations marks a significant milestone in Boehringer Ingelheim's decarbonization strategy," said Andy Brehm, Executive Director, U.S. Site ...
Boehringer Ingelheim to evaluate combination of DLL3-targeting T-cell engager plus PD-L1/VEGF-A bispecific antibody in small cell lung cancer: Ingelheim, Germany Saturday, April 1 ...
Boehringer Ingelheim has amended its partnership with Click Therapeutics on a digital therapeutic (DTx) for schizophrenia, ...
European leaders are welcoming Péter Magyar's election victory in Hungary, and the fall from power of long-serving Prime ...
German pharma Boehringer Ingelheim has handed full commercial and marketing rights for digital schizophrenia therapy CT-155 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results